Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AxS 007

Next Previous
Drug Profile

AxS 007

Alternative Names: AxS-007

Latest Information Update: 03 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanocarry Therapeutics
  • Developer Nanocarry Therapeutics; National Cancer Institute (USA)
  • Class Antibodies; Antineoplastics; Drug conjugates
  • Mechanism of Action Erb-b2 receptor tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain metastases

Most Recent Events

  • 02 Jun 2026 Adverse event and pharmacodynamics data from a preclinical in Brain metastases presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO 2026)
  • 04 Sep 2024 Nanocarry Therapeutics and National Cancer Institute (NCI) USA enters into a collaboration agreement for comprehensive preclinical characterization of AxS 007
  • 04 Sep 2024 Preclinical trials in Brain metastases in Israel (unspecified route) prior to September 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top